Eckert & Ziegler Strahlen- und Medizintechnik AG (EUZ:XETRA) Stock Forecast
Alert
Its only available to paid users.
N/A
Based on the Eckert & Ziegler Strahlen- und Medizintechnik AG stock forecast from 0 analysts, the average analyst target price for Eckert & Ziegler Strahlen- und Medizintechnik AG is not available over the next 12 months. Eckert & Ziegler Strahlen- und Medizintechnik AG’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Eckert & Ziegler Strahlen- und Medizintechnik AG is Neutral, which is based on 7 positive signals and 7 negative signals. At the last closing, Eckert & Ziegler Strahlen- und Medizintechnik AG’s stock price was EUR 36.50. Eckert & Ziegler Strahlen- und Medizintechnik AG’s stock price has changed by +8.37% over the past week, -2.20% over the past month and -21.67% over the last year.
No recent analyst target price found for Eckert & Ziegler Strahlen- und Medizintechnik AG
No recent average analyst rating found for Eckert & Ziegler Strahlen- und Medizintechnik AG
Company Overview Eckert & Ziegler Strahlen- und Medizintechnik AG
Eckert & Ziegler SE, through its subsidiaries, manufactures and sells isotope technology components for medical, scientific, and industrial applications worldwide. It operates in two segments, Medical and Isotope Products. The Medical segment offers small radioactive implants for the treatment of prostate cancer seeds; and eye application based on ruthenium-106 or iodine-125 for treating uveal melanoma. This segment also provides radiopharmaceuticals, laboratory equipment, radiosynthesis equipment, quality-control equipment, and other consumables. The Isotope Products segment manufactures and sells standard and radiation sources for medical and industrial sectors. This segment offers calibration related sources for radioisotopes. The company was formerly known as Eckert & Ziegler Strahlen- und Medizintechnik AG and changed its to Eckert & Ziegler SE in March 2024. Eckert & Ziegler SE was founded in 1992 and is based in Berlin, Germany. Address: Robert-Rössle-Strasse 10, Berlin, Germany, 13125 Read Less
Eckert & Ziegler SE, through its subsidiaries, manufactures and sells isotope technology components for medical, scientific, and industrial applications worldwide. It operates in two segments, Medical and Isotope Products. The Medical segment offers small radioactive implants for...Read More
Frequently Asked Questions About Eckert & Ziegler Strahlen- und Medizintechnik AG (EUZ:XETRA) Stock
Stock Target Advisor's fundamental analysis for Eckert & Ziegler Strahlen- und Medizintechnik AG's stock is Neutral.
EUZ:XETRA stock's dividend yield is 1.34%.
Our analysis grades EUZ:XETRA stock's dividend yield at F. This means that EUZ:XETRA stock's dividend yield is above 13% of the stocks in the Medical Devices sector in the XETRA exchange.
Based on this EUZ:XETRA may be a poor dividend stock for its sector.
Unfortunately we do not have enough data on EUZ:XETRA's stock to indicate what its average analyst target is.
EUZ:XETRA stock's Price/Earning ratio is 25.47.
Our analysis grades EUZ:XETRA stock's Price / Earning ratio at F. This means that EUZ:XETRA stock's Price/Earning ratio is above 43.99999999999999% of the stocks in the Medical Devices sector in the XETRA exchange.
Based on this EUZ:XETRA may be fairly valued for its sector
The last closing price of EUZ:XETRA's stock was EUR 36.50.
The most recent market capitalization for EUZ:XETRA is EUR 0.77B.
Unfortunately we do not have enough analyst data on EUZ:XETRA's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Eckert & Ziegler Strahlen- und Medizintechnik AG's stock.
As per our most recent records Eckert & Ziegler Strahlen- und Medizintechnik AG has 1,075 Employees.
Eckert & Ziegler Strahlen- und Medizintechnik AG's registered address is Robert-Rössle-Strasse 10, Berlin, Germany, 13125.
You can get more information about it from Eckert & Ziegler Strahlen- und Medizintechnik AG's website at https://www.ezag.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low debt
The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Below median total returns
The company has under performed its peers on annual average total returns in the past 5 years.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for EUZ:XETRA !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
Stocktwits
